HTERT: Another brick in the wall of cancer cells

Mutation Research - Reviews in Mutation Research

Volumn 752, Issue 2, 2013, Pages 119-128

  Lamy, Evelyn ^a   Goetz, Victoria ^a   Erlacher, Miriam ^a   Herz, Corinna ^a   Mersch Sundermann, Volker ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Chemo resistance of cancer cells; DNA damage response; HTERT; Telomerase

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; BRCA1 PROTEIN; C RAF PROTEIN; CISPLATIN; CYTARABINE; DNA; DOXORUBICIN; ETOPOSIDE; HEAT SHOCK PROTEIN 90; HISTONE H3; HYDROXYUREA; MAX PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MAD1; PROTEIN MCL 1; PROTEIN P53; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; STAUROSPORINE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; TERT PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENOTOXICITY; HISTONE ACETYLATION; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TELOMERE; TUMOR CELL LINE; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

APOPTOSIS; DNA DAMAGE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 84876790989     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2012.12.005     Document Type: Review

References (180)

1. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 1997, 33:787-791.
2. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
3. Mansfield L., Subramanian A., Devalia H., Jiang W., Newbold R.F., Mokbel K. HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR. Anticancer Res. 2007, 27:2265-2268.
4. Dahse R., Fiedler W., Ernst G. Telomeres and telomerase: biological and clinical importance. Clin. Chem. 1997, 43:708-714.
5. Smogorzewska A., de Lange T. Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 2004, 73:177-208.
6. Albanell J., Lonardo F., Rusch V., Engelhardt M., Langenfeld J., Han W., Klimstra D., Venkatraman E., Moore M.A., Dmitrovsky E. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J. Natl. Cancer Inst. 1997, 89:1609-1615.
7. Triginelli S.A., Silva-Filho A.L., Traiman P., Silva F.M., Chaves-Dias M.C., Oliveira G.C., Cunha-Melo J.R. Telomerase activity in the vaginal margins of radical hysterectomy in patients with carcinoma of the cervix: correlation with histology and human papillomavirus. Int. J. Gynecol. Cancer 2006, 16:1283-1288.
8. Uen Y.H., Lin S.R., Wu D.C., Su Y.C., Wu J.Y., Cheng T.L., Chi C.W., Wang J.Y. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann. Surg. 2007, 246:1040-1046.
9. Bryan T.M., Sperger J.M., Chapman K.B., Cech T.R. Telomerase reverse transcriptase genes identified in Tetrahymena thermophila and Oxytricha trifallax. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8479-8484.
10. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J., et al. The RNA component of human telomerase. Science 1995, 269:1236-1241.
11. Chang J.T., Chen Y.L., Yang H.T., Chen C.Y., Cheng A.J. Differential regulation of telomerase activity by six telomerase subunits. Eur. J. Biochem. 2002, 269:3442-3450.
12. Holt S.E., Aisner D.L., Baur J., Tesmer V.M., Dy M., Ouellette M., Trager J.B., Morin G.B., Toft D.O., Shay J.W., Wright W.E., White M.A. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. 1999, 13:817-826.
13. Ito H., Kyo S., Kanaya T., Takakura M., Inoue M., Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin. Cancer Res. 1998, 4:1603-1608.
14. Mukherjee S., Firpo E.J., Wang Y., Roberts J.M. Separation of telomerase functions by reverse genetics. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E1363-E1371.
15. Sharma G.G., Gupta A., Wang H., Scherthan H., Dhar S., Gandhi V., Iliakis G., Shay J.W., Young C.S., Pandita T.K. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 2003, 22:131-146.
16. Cao Y., Li H., Deb S., Liu J.P. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002, 21:3130-3138.
17. Masutomi K., Possemato R., Wong J.M., Currier J.L., Tothova Z., Manola J.B., Ganesan S., Lansdorp P.M., Collins K., Hahn W.C. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8222-8227.
18. Shin K.H., Kang M.K., Dicterow E., Kameta A., Baluda M.A., Park N.H. Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity. Clin. Cancer Res. 2004, 10:2551-2560.
19. Zhang P., Chan S.L., Fu W., Mendoza M., Mattson M.P. TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability. FASEB J. 2003, 17:767-769.
20. Akiyama M., Yamada O., Kanda N., Akita S., Kawano T., Ohno T., Mizoguchi H., Eto Y., Anderson K.C., Yamada H. Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett. 2002, 178:187-197.
21. Xi L., Chen G., Zhou J., Xu G., Wang S., Wu P., Zhu T., Zhang A., Yang W., Xu Q., Lu Y., Ma D. Inhibition of telomerase enhances apoptosis induced by sodium butyrate via mitochondrial pathway. Apoptosis 2006, 11:789-798.
22. Bermudez Y., Erasso D., Johnson N.C., Alfonso M.Y., Lowell N.E., Kruk P.A. Telomerase confers resistance to caspase-mediated apoptosis. Clin. Interv. Aging 2006, 1:155-167.
23. Choi Y.H. Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity. Int. J. Oncol. 2006, 29:1207-1213.
24. Gorbunova V., Seluanov A., Pereira-Smith O.M. Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J. Biol. Chem. 2002, 277:38540-38549.
25. Wesbuer S., Lanvers-Kaminsky C., Duran-Seuberth I., Bolling T., Schafer K.L., Braun Y., Willich N., Greve B. Association of telomerase activity with radio- and chemosensitivity of neuroblastomas. Radiat. Oncol. 2010, 5:66.
26. Ahmed S., Passos J.F., Birket M.J., Beckmann T., Brings S., Peters H., Birch-Machin M.A., von Zglinicki T., Saretzki G. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J. Cell Sci. 2008, 121:1046-1053.
27. Luiten R.M., Pene J., Yssel H., Spits H. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis. Blood 2003, 101:4512-4519.
28. Huang X.Q., Wang J., Liu J.P., Feng H., Liu W.B., Yan Q., Liu Y., Sun S.M., Deng M., Gong L., Liu Y., Li D.W. hTERT extends proliferative lifespan and prevents oxidative stress-induced apoptosis in human lens epithelial cells. Invest. Ophthalmol. Vis. Sci. 2005, 46:2503-2513.
29. Ren J.G., Xia H.L., Tian Y.M., Just T., Cai G.P., Dai Y.R. Expression of telomerase inhibits hydroxyl radical-induced apoptosis in normal telomerase negative human lung fibroblasts. FEBS Lett. 2001, 488:133-138.
30. Indran I.R., Hande M.P., Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res. 2011, 71:266-276.
31. Dudognon C., Pendino F., Hillion J., Saumet A., Lanotte M., Segal-Bendirdjian E. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 2004, 23:7469-7474.
32. Li P., Hou M., Lou F., Bjorkholm M., Xu D. Telomere dysfunction induced by chemotherapeutic agents and radiation in normal human cells. Int. J. Biochem. Cell Biol. 2012, 44:1531-1540.
33. Jeyapalan J., Leake A., Ahmed S., Saretzki G., Tilby M., von Zglinicki T. The role of telomeres in etoposide induced tumor cell death. Cell Cycle 2004, 3:1169-1176.
34. Klapper W., Qian W., Schulte C., Parwaresch R. DNA damage transiently increases TRF2 mRNA expression and telomerase activity. Leukemia 2003, 17:2007-2015.
35. Moriarty T.J., Dupuis S., Autexier C. Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide. Leukemia 2002, 16:1112-1120.
36. Sato N., Mizumoto K., Kusumoto M., Nishio S., Maehara N., Urashima T., Ogawa T., Tanaka M. Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide. Br. J. Cancer 2000, 82:1819-1826.
37. Ning H., Li T., Zhao L., Li T., Li J., Liu J., Liu Z., Fan D. TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol. Ther. 2006, 5:950-956.
38. Malerba I., Gribaldo L., Diodovich C., Carloni M., Meschini R., Bowe G., Collotta A. Induction of apoptosis and inhibition of telomerase activity in human bone marrow and HL-60 p53 null cells treated with anti-cancer drugs. Toxicol. In Vitro 2005, 19:523-532.
39. Lin Z., Lim S., Viani M.A., Sapp M., Lim M.S. Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am. J. Pathol. 2001, 159:711-719.
40. Akiyama M., Horiguchi-Yamada J., Saito S., Hoshi Y., Yamada O., Mizoguchi H., Yamada H. Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur. J. Cancer 1999, 35:309-315.
41. Li D.J., Zhang Y.Z., Meng F.K., Zhang D.H., Liu W.L. Regulative function of extracellular regulated protein kinases and telomerase in apoptosis of hepatocarcinomatous and leukemic cell lines. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002, 10:294-298.
42. Faraoni I., Turriziani M., Masci G., De Vecchis L., Shay J.W., Bonmassar E., Graziani G. Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin. Cancer Res. 1997, 3:579-585.
43. Soares J., Lowe M.M., Jarstfer M.B. The catalytic subunit of human telomerase is a unique caspase-6 and caspase-7 substrate. Biochemistry 2011, 50:9046-9055.
44. Fu W., Begley J.G., Killen M.W., Mattson M.P. Anti-apoptotic role of telomerase in pheochromocytoma cells. J. Biol. Chem. 1999, 274:7264-7271.
45. Del Bufalo D., Rizzo A., Trisciuoglio D., Cardinali G., Torrisi M.R., Zangemeister-Wittke U., Zupi G., Biroccio A. Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death Differ. 2005, 12:1429-1438.
46. Cerone M.A., Londono-Vallejo J.A., Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol. Cancer Ther. 2006, 5:1669-1675.
47. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen R.L., Knoll J.H., Meyerson M., Weinberg R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 1999, 5:1164-1170.
48. Poynter K.R., Sachs P.C., Bright A.T., Breed M.S., Nguyen B.N., Elmore L.W., Holt S.E. Genetic inhibition of telomerase results in sensitization and recovery of breast tumor cells. Mol. Cancer Ther. 2009, 8:1319-1327.
49. Nguyen B.N., Elmore L.W., Holt S.E. Mechanism of dominant-negative telomerase function. Cell Cycle 2009, 8:3227-3233.
50. Massard C., Zermati Y., Pauleau A.L., Larochette N., Metivier D., Sabatier L., Kroemer G., Soria J.C. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 2006, 25:4505-4514.
51. Gao X.D., Chen Y.R. Inhibition of telomerase with human telomerase reverse transcriptase antisense enhances tumor necrosis factor-alpha-induced apoptosis in bladder cancer cells. Chin. Med. J. (Engl.) 2007, 120:755-760.
52. Guo X., Wang W., Zhou F., Lu Z., Fang R., Jia F., Bu X., Li R., Zhang B., Wu M., Wei L. siRNA-mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma. Cancer Biol. Ther. 2008, 7:1555-1560.
53. Luo Y., Yi Y., Yao Z. Growth arrest in ovarian cancer cells by hTERT inhibition short-hairpin RNA targeting human telomerase reverse transcriptase induces immediate growth inhibition but not necessarily induces apoptosis in ovarian cancer cells. Cancer Invest. 2009, 27:960-970.
54. Fu W., Killen M., Culmsee C., Dhar S., Pandita T.K., Mattson M.P. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function. J. Mol. Neurosci. 2000, 14:3-15.
55. Gandellini P., Folini M., Bandiera R., De Cesare M., Binda M., Veronese S., Daidone M.G., Zunino F., Zaffaroni N. Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem. Pharmacol. 2007, 73:1703-1714.
56. Gao X.D., Chen Y.R. Inhibition of telomerase with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells. Asian J. Androl. 2007, 9:697-704.
57. Kondoh K., Tsuji N., Asanuma K., Kobayashi D., Watanabe N. Inhibition of estrogen receptor beta-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-delta(12,14)-prostaglandin J(2)-induced apoptosis in cancer cells. Exp. Cell Res. 2007, 313:3486-3496.
58. Dong X., Liu A., Zer C., Feng J., Zhen Z., Yang M., Zhong L. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer 2009, 9:133.
59. Du Q.Y., Wang X.B., Chen X.J., Zheng W., Wang S.Q. Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase. World J. Gastroenterol. 2003, 9:2030-2035.
60. Miri-Moghaddam E., Deezagi A., Soheili Z.S., Shariati P. Apoptosis and reduced cell proliferation of HL-60 cell line caused by human telomerase reverse transcriptase inhibition by siRNA. Acta Haematol. 2010, 124:72-78.
61. Qian X., Cheng J., Chen A., Wang Y., Tao Y., Cao J., Feng Z. Long-term effects of short hairpin RNA-targeted human telomerase reverse transcriptase on suppression of SGC-7901 cell proliferation by inhibition of telomerase activity. Oncol. Rep. 2008, 19:575-581.
62. Tao Z., Chen S., Wu Z., Xiao B., Liu J., Hou W. Targeted therapy of human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides directed against telomerase reverse transcriptase mRNA. J. Laryngol. Otol. 2005, 119:92-96.
63. Wang Y.F., Guo K.J., Huang B.T., Liu Y., Tang X.Y., Zhang J.J., Xia Q. Inhibitory effects of antisense phosphorothioate oligodeoxynucleotides on pancreatic cancer cell Bxpc-3 telomerase activity and cell growth in vitro. World J. Gastroenterol. 2006, 12:4004-4008.
64. Wang R., Lin F., Wang X., Gao P., Dong K., Wei S.H., Cheng S.Y., Zhang H.Z. The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. Cancer Biol. Ther. 2007, 6:1295-1301.
65. Zhong Y.Q., Xia Z.S., Fu Y.R., Zhu Z.H. Knockdown of hTERT by SiRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2. J. Dig. Dis. 2010, 11:176-184.
66. Teng L., Specht M.C., Barden C.B., Fahey T.J. Antisense hTERT inhibits thyroid cancer cell growth. J. Clin. Endocrinol. Metab. 2003, 88:1362-1366.
67. Zheng J.N., Sun Y.F., Pei D.S., Liu J.J., Chen J.C., Li W., Sun X.Q., Shi Q.D., Han R.F., Ma T.X. Inhibition of proliferation and induction of apoptosis in human renal carcinoma cells by anti-telomerase small interfering RNAs. Acta Biochim. Biophys. Sin. (Shanghai) 2006, 38:500-506.
68. Folini M., Brambilla C., Villa R., Gandellini P., Vignati S., Paduano F., Daidone M.G., Zaffaroni N. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur. J. Cancer 2005, 41:624-634.
69. Folini M., Bandiera R., Millo E., Gandellini P., Sozzi G., Gasparini P., Longoni N., Binda M., Daidone M.G., Berg K., Zaffaroni N. Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. Cell Prolif. 2007, 40:905-920.
70. Dairkee S.H., Nicolau M., Sayeed A., Champion S., Ji Y., Moore D.H., Yong B., Meng Z., Jeffrey S.S. Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. Oncogene 2007, 26:6269-6279.
71. Jiang Y.A., Luo H.S., Zhang Y.Y., Fan L.F., Jiang C.Q., Chen W.J. Telomerase activity and cell apoptosis in colon cancer cell by human telomerase reverse transcriptase gene antisense oligodeoxynucleotide. World J. Gastroenterol. 2003, 9:1981-1984.
72. Chen S.M., Tao Z.Z., Hua Q.Q., Xiao B.K., Xu Y., Wang Y., Deng Y.Q. Inhibition of telomerase activity in cancer cells using short hairpin RNA expression vectors. Cancer Invest. 2007, 25:691-698.
73. Kraemer K., Fuessel S., Schmidt U., Kotzsch M., Schwenzer B., Wirth M.P., Meye A. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. 2003, 9:3794-3800.
74. Miri-Moghaddam E., Deezagi A., Soheili Z.S. Downregulation of telomerase activity in human promyelocytic cell line using RNA interference. Ann. Hematol. 2009, 88:1169-1176.
75. Pallini R., Sorrentino A., Pierconti F., Maggiano N., Faggi R., Montano N., Maira G., Larocca L.M., Levi A., Falchetti M.L. Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int. J. Cancer 2006, 118:2158-2167.
76. Zhang P.H., Zou L., Tu Z.G. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J. Surg. Res. 2006, 131:143-149.
77. Zou L., Zhang P., Luo C., Tu Z. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother. Pharmacol. 2006, 57:328-334.
78. Lai S.R., Cunningham A.P., Huynh V.Q., Andrews L.G., Tollefsbol T.O. Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop. Exp. Cell Res. 2007, 313:322-330.
79. Park Y.P., Kim K.D., Kang S.H., Yoon do Y., Park J.W., Kim J.W., Lee H.G. Human telomerase reverse transcriptase (hTERT): a target molecule for the treatment of cisplatin-resistant tumors. Korean J. Lab. Med. 2008, 28:430-437.
80. Wu Y.L., Dudognon C., Nguyen E., Hillion J., Pendino F., Tarkanyi I., Aradi J., Lanotte M., Tong J.H., Chen G.Q., Segal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J. Cell Sci. 2006, 119:2797-2806.
81. Counter C.M., Meyerson M., Eaton E.N., Ellisen L.W., Caddle S.D., Haber D.A., Weinberg R.A. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16:1217-1222.
82. Haendeler J., Drose S., Buchner N., Jakob S., Altschmied J., Goy C., Spyridopoulos I., Zeiher A.M., Brandt U., Dimmeler S. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler. Thromb. Vasc. Biol. 2009, 29:929-935.
83. Indran I.R., Hande M.P., Pervaiz S. Tumor cell redox state and mitochondria at the center of the non-canonical activity of telomerase reverse transcriptase. Mol. Aspects Med. 2010, 31:21-28.
84. Pizzimenti S., Briatore F., Laurora S., Toaldo C., Maggio M., De Grandi M., Meaglia L., Menegatti E., Giglioni B., Dianzani M.U., Barrera G. 4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radic. Biol. Med. 2006, 40:1578-1591.
85. Pizzimenti S., Menegatti E., Berardi D., Toaldo C., Pettazzoni P., Minelli R., Giglioni B., Cerbone A., Dianzani M.U., Ferretti C., Barrera G. 4-Hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity. J. Nutr. Biochem. 2010, 21:818-826.
86. Kyo S., Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy?. Oncogene 2002, 21:688-697.
87. Haendeler J., Hoffmann J., Brandes R.P., Zeiher A.M., Dimmeler S. Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of tyrosine 707. Mol. Cell. Biol. 2003, 23:4598-4610.
88. Kyo S., Masutomi K., Maida Y., Kanaya T., Yatabe N., Nakamura M., Tanaka M., Takarada M., Sugawara I., Murakami S., Taira T., Inoue M. Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase. Am. J. Pathol. 2003, 163:859-867.
89. 2 is Src kinase dependent. Exp. Gerontol. 2010, 45:558-562.
90. Santos J.H., Meyer J.N., Skorvaga M., Annab L.A., Van Houten B. Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. Aging Cell 2004, 3:399-411.
91. Santos J.H., Meyer J.N., Van Houten B. Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis. Hum. Mol. Genet. 2006, 15:1757-1768.
92. Seimiya H., Sawada H., Muramatsu Y., Shimizu M., Ohko K., Yamane K., Tsuruo T. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J. 2000, 19:2652-2661.
93. Majerska J., Sykorova E., Fajkus J. Non-telomeric activities of telomerase. Mol. Biosyst. 2011, 7:1013-1023.
94. Gordon D.M., Santos J.H. The emerging role of telomerase reverse transcriptase in mitochondrial DNA metabolism. J. Nucleic Acids 2010, 287(24):20737-20747.
95. Wang J.Y. DNA damage and apoptosis. Cell Death Differ. 2001, 8:1047-1048.
96. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol. Cell 2007, 28:739-745.
97. Bensimon A., Aebersold R., Shiloh Y. Beyond ATM: the protein kinase landscape of the DNA damage response. FEBS Lett. 2011, 585:1625-1639.
98. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
99. Perrault S.D., Hornsby P.J., Betts D.H. Global gene expression response to telomerase in bovine adrenocortical cells. Biochem. Biophys. Res. Commun. 2005, 335:925-936.
100. Cong Y., Shay J.W. Actions of human telomerase beyond telomeres. Cell Res. 2008, 18:725-732.
101. Xiong J., Fan S., Meng Q., Schramm L., Wang C., Bouzahza B., Zhou J., Zafonte B., Goldberg I.D., Haddad B.R., Pestell R.G., Rosen E.M. BRCA1 inhibition of telomerase activity in cultured cells. Mol. Cell. Biol. 2003, 23:8668-8690.
102. Li H., Lee T.H., Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 2002, 277:20965-20973.
103. Zhou C., Liu J. Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells. Biochem. Biophys. Res. Commun. 2003, 303:130-136.
104. Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y., Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y., Saya H. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 2002, 7:1173-1182.
105. Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., Hatakeyama K., Saya H. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114:585-598.
106. Fu J., Bian M., Jiang Q., Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol. Cancer Res. 2007, 5:1-10.
107. Yang H., Ou C.C., Feldman R.I., Nicosia S.V., Kruk P.A., Cheng J.Q. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004, 64:463-467.
108. Kharbanda S., Kumar V., Dhar S., Pandey P., Chen C., Majumder P., Yuan Z.M., Whang Y., Strauss W., Pandita T.K., Weaver D., Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr. Biol. 2000, 10:568-575.
109. Baskaran R., Wood L.D., Whitaker L.L., Canman C.E., Morgan S.E., Xu Y., Barlow C., Baltimore D., Wynshaw-Boris A., Kastan M.B., Wang J.Y. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997, 387:516-519.
110. Sun X., Majumder P., Shioya H., Wu F., Kumar S., Weichselbaum R., Kharbanda S., Kufe D. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J. Biol. Chem. 2000, 275:17237-17240.
111. Yuan Z.M., Utsugisawa T., Huang Y., Ishiko T., Nakada S., Kharbanda S., Weichselbaum R., Kufe D. Inhibition of phosphatidylinositol 3-kinase by c-Abl in the genotoxic stress response. J. Biol. Chem. 1997, 272:23485-23488.
112. Harrington L.A., Greider C.W. Telomerase primer specificity and chromosome healing. Nature 1991, 353:451-454.
113. Stellwagen A.E., Haimberger Z.W., Veatch J.R., Gottschling D.E. Ku interacts with telomerase RNA to promote telomere addition at native and broken chromosome ends. Genes Dev. 2003, 17:2384-2395.
114. Flint J., Craddock C.F., Villegas A., Bentley D.P., Williams H.J., Galanello R., Cao A., Wood W.G., Ayyub H., Higgs D.R. Healing of broken human chromosomes by the addition of telomeric repeats. Am. J. Hum. Genet. 1994, 55:505-512.
115. Jentsch S., Tobler H., Muller F. New telomere formation during the process of chromatin diminution in Ascaris suum. Int. J. Dev. Biol. 2002, 46:143-148.
116. Morin G.B. Recognition of a chromosome truncation site associated with alpha-thalassaemia by human telomerase. Nature 1991, 353:454-456.
117. Huard S., Autexier C. Human telomerase catalyzes nucleolytic primer cleavage. Nucleic Acids Res. 2004, 32:2171-2180.
118. Azzalin C.M., Nergadze S.G., Giulotto E. Human intrachromosomal telomeric-like repeats: sequence organization and mechanisms of origin. Chromosoma 2001, 110:75-82.
119. Rebuzzini P., Khoriauli L., Azzalin C.M., Magnani E., Mondello C., Giulotto E. New mammalian cellular systems to study mutations introduced at the break site by non-homologous end-joining. DNA Repair (Amst.) 2005, 4:546-555.
120. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
121. Viniegra J.G., Martinez N., Modirassari P., Hernandez Losa J., Parada Cobo C., Sanchez-Arevalo Lobo V.J., Aceves Luquero C.I., Alvarez-Vallina L., Ramon y Cajal S., Rojas J.M., Sanchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem. 2005, 280:4029-4036.
122. Cong Y.S., Wright W.E., Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 2002, 66:407-425. table of contents.
123. Kang S.S., Kwon T., Kwon D.Y., Do S.I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 1999, 274:13085-13090.
124. Haendeler J., Hoffmann J., Rahman S., Zeiher A.M., Dimmeler S. Regulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation. FEBS Lett. 2003, 536:180-186.
125. Akiyama M., Hideshima T., Hayashi T., Tai Y.T., Mitsiades C.S., Mitsiades N., Chauhan D., Richardson P., Munshi N.C., Anderson K.C. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003, 63:18-21.
126. Kimura A., Ohmichi M., Kawagoe J., Kyo S., Mabuchi S., Takahashi T., Ohshima C., Arimoto-Ishida E., Nishio Y., Inoue M., Kurachi H., Tasaka K., Murata Y. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004, 23:4505-4515.
127. Kawagoe J., Ohmichi M., Takahashi T., Ohshima C., Mabuchi S., Takahashi K., Igarashi H., Mori-Abe A., Saitoh M., Du B., Ohta T., Kimura A., Kyo S., Inoue M., Kurachi H. Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. J. Biol. Chem. 2003, 278:43363-43372.
128. Kawauchi K., Ihjima K., Yamada O. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J. Immunol. 2005, 174:5261-5269.
129. Tonic I., Yu W.N., Park Y., Chen C.C., Hay N. Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J. Biol. Chem. 2010, 285:23790-23798.
130. Xiang T., Ohashi A., Huang Y., Pandita T.K., Ludwig T., Powell S.N., Yang Q. Negative regulation of AKT activation by BRCA1. Cancer Res. 2008, 68:10040-10044.
131. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
132. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
133. Alfonso-De Matte M.Y., Yang H., Evans M.S., Cheng J.Q., Kruk P.A. Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res. 2002, 62:4575-4578.
134. Takakura M., Kyo S., Inoue M., Wright W.E., Shay J.W. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol. Cell. Biol. 2005, 25:8037-8043.
135. Potapova O., Basu S., Mercola D., Holbrook N.J. Protective role for c-Jun in the cellular response to DNA damage. J. Biol. Chem. 2001, 276:28546-28553.
136. Rawlings J.S., Rosler K.M., Harrison D.A. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117:1281-1283.
137. Konnikova L., Simeone M.C., Kruger M.M., Kotecki M., Cochran B.H. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 2005, 65:6516-6520.
138. Nakatake M., Kakiuchi Y., Sasaki N., Murakami-Murofushi K., Yamada O. STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle 2007, 6:1496-1501.
139. Li H., Liu J.P. Mechanisms of action of TGF-beta in cancer: evidence for Smad3 as a repressor of the hTERT gene. Ann. N.Y. Acad. Sci. 2007, 1114:56-68.
140. Li H., Xu D., Li J., Berndt M.C., Liu J.P. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 2006, 281:25588-25600.
141. Lacerte A., Korah J., Roy M., Yang X.J., Lemay S., Lebrun J.J. Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors. Cell. Signal. 2008, 20:50-59.
142. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 1999, 21:220-224.
143. Greenberg R.A., O'Hagan R.C., Deng H., Xiao Q., Hann S.R., Adams R.R., Lichtsteiner S., Chin L., Morin G.B., DePinho R.A. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999, 18:1219-1226.
144. Kyo S., Takakura M., Taira T., Kanaya T., Itoh H., Yutsudo M., Ariga H., Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000, 28:669-677.
145. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999, 59:551-557.
146. Gunes C., Lichtsteiner S., Vasserot A.P., Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 2000, 60:2116-2121.
147. Zhu J., Blenis J., Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6584-6589.
148. Chou C.K., Lee D.F., Sun H.L., Li L.Y., Lin C.Y., Huang W.C., Hsu J.M., Kuo H.P., Yamaguchi H., Wang Y.N., Liu M., Wu H.Y., Liao P.C., Yen C.J., Hung M.C. The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. Mol. Carcinog. 2009, 48:1048-1058.
149. Liu L., Saldanha S.N., Pate M.S., Andrews L.G., Tollefsbol T.O. Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer 2004, 41:26-37.
150. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99:1528-1538.
151. Dwyer J., Li H., Xu D., Liu J.P. Transcriptional regulation of telomerase activity: roles of the Ets transcription factor family. Ann. N.Y. Acad. Sci. 2007, 1114:36-47.
152. Ge Z., Liu C., Bjorkholm M., Gruber A., Xu D. Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation. Mol. Cell. Biol. 2006, 26:230-237.
153. Liu Y., Kulesz-Martin M. P53 regulation and function in normal cells and tumors. Medicina (B Aires) 2000, 60(Suppl. 2):9-11.
154. Tapia N., Scholer H.R. p53 connects tumorigenesis and reprogramming to pluripotency. J. Exp. Med. 2010, 207:2045-2048.
155. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996, 10:1054-1072.
156. Xu D., Wang Q., Gruber A., Bjorkholm M., Chen Z., Zaid A., Selivanova G., Peterson C., Wiman K.G., Pisa P. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 2000, 19:5123-5133.
157. Kanaya T., Kyo S., Hamada K., Takakura M., Kitagawa Y., Harada H., Inoue M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 2000, 6:1239-1247.
158. Kusumoto M., Ogawa T., Mizumoto K., Ueno H., Niiyama H., Sato N., Nakamura M., Tanaka M. Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clin. Cancer Res. 1999, 5:2140-2147.
159. Toh W.H., Kyo S., Sabapathy K. Relief of p53-mediated telomerase suppression by p73. J. Biol. Chem. 2005, 280:17329-17338.
160. Rahman R., Latonen L., Wiman K.G. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene 2005, 24:1320-1327.
161. Yao Y., Bellon M., Shelton S.N., Nicot C. Tumor suppressors p53, p63TAalpha, p63TAy, p73alpha, and p73beta use distinct pathways to repress telomerase expression. J. Biol. Chem. 2012, 287:20737-20747.
162. Li H., Cao Y., Berndt M.C., Funder J.W., Liu J.P. Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro. Oncogene 1999, 18:6785-6794.
163. Maxwell S.A., Capp D., Acosta S.A. Telomerase activity in immortalized endothelial cells undergoing p53-mediated apoptosis. Biochem. Biophys. Res. Commun. 1997, 241:642-645.
164. Kobayashi T., Sugawara Y., Shi Y.Z., Makuuchi M. Telomerase expression and p53 status in hepatocellular carcinoma. Am. J. Gastroenterol. 2002, 97:3166-3171.
165. Zhu J., Jiang J., Zhou W., Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998, 58:5061-5065.
166. Racek T., Mise N., Li Z., Stoll A., Putzer B.M. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J. Biol. Chem. 2005, 280:40402-40405.
167. Beitzinger M., Oswald C., Beinoraviciute-Kellner R., Stiewe T. Regulation of telomerase activity by the p53 family member p73. Oncogene 2006, 25:813-826.
168. Adams J.M., Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 2001, 26:61-66.
169. Wyllie A.H. Where, O death, is thy sting? A brief review of apoptosis biology. Mol. Neurobiol. 2010, 42:4-9.
170. Zinkel S., Gross A., Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006, 13:1351-1359.
171. Park Y.P., Choi S.C., Cho M.Y., Song E.Y., Kim J.W., Paik S.G., Kim Y.K., Kim J.W., Lee H.G. Modulation of telomerase activity and human telomerase reverse transcriptase expression by caspases and bcl-2 family proteins in Cisplatin-induced cell death. Korean J. Lab. Med. 2006, 26:287-293.
172. Mandal M., Kumar R. Bcl-2 modulates telomerase activity. J. Biol. Chem. 1997, 272:14183-14187.
173. Sikand K., Kaul D., Varma N. Receptor Ck-dependent signaling regulates hTERT gene transcription. BMC Cell Biol. 2006, 7:2.
174. MacNamara B., Wang W., Chen Z., Hou M., Mazur J., Gruber A., Porwit-MacDonald A. Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin's lymphomas. Haematologica 2001, 86:386-393.
175. Wang Q., Gao F., May W.S., Zhang Y., Flagg T., Deng X. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol. Cell 2008, 29:488-498.
176. Liu Y., Naumovski L., Hanawalt P. Nucleotide excision repair capacity is attenuated in human promyelocytic HL60 cells that overexpress BCL2. Cancer Res. 1997, 57:1650-1653.
177. Youn C.K., Cho H.J., Kim S.H., Kim H.B., Kim M.H., Chang I.Y., Lee J.S., Chung M.H., Hahm K.S., You H.J. Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat. Cell Biol. 2005, 7:137-147.
178. Zhao J., Gao F., Zhang Y., Wei K., Liu Y., Deng X. Bcl2 inhibits abasic site repair by down-regulating APE1 endonuclease activity. J. Biol. Chem. 2008, 283:9925-9932.
179. Jin Z., May W.S., Gao F., Flagg T., Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J. Biol. Chem. 2006, 281:14446-14456.
180. Tamakawa R.A., Fleisig H.B., Wong J.M. Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner. Cancer Res. 2010, 70:8684-8694.